Agranulocytosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Bot: Removing from Primary care)
 
(11 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{SI}}
{{SI}}
{{CMG}}; {{AE}}  {{DG}}  {{N.F}}
{{CMG}} {{shyam}}; {{AE}}  {{DG}}  {{N.F}}


'''''Synonyms and Keywords''''': Agranulosis, granulocytopenia, neutropenia
'''''Synonyms and Keywords''''': Agranulosis, granulocytopenia, neutropenia
==Overview==
==Overview==
'''[[Agranulocytosis]]''' is a [[Hematology|hematological]] disorder characterized by the acute-onset of severe [[neutropenia]]. Neutrophils - a subset of [[white blood cell]] - normally make up 50-70% of circulating white blood cells and serve as the primary defense against [[infection]]s. Hence, patients with neutropenia are more susceptible to infections, mainly bacterial; without prompt medical attention, the condition is often life-threatening. Similar to severe neutropenia in the setting of infection, cases related to [[cytotoxic]] [[chemotherapy]], [[hematopoietic stem cell]] transplant, or other causes of [[bone marrow suppression]] are considered a medical emergency.
Agranulocytosis is defined as marked reduction in the number of [[Granulocyte|granulocytes]] ([[Neutrophils]], [[Basophils]], [[Eosinophils]]) below an absolute count of 500 cells/mcL. It is a rare condition with [[incidence]] of 1 to 5 cases per million population per year. Agranulocytosis results in frequent chronic [[Bacterial infection|bacterial infections]] of skin, [[lung]], and [[throat]]. Patients can present with [[sepsis]] and [[fever]]. Among many risk factors, [[Medications|medications,]] combination therapy with [[Angiotensin Converting Enzyme Inhibitor|ACE inhibitors]] and [[interferon]], [[List of chemotherapeutic agents#Cytotoxic Chemotherapy|cytotoxic chemotherapy]], [[Hematologic malignancy|hematologic malignancies]], and [[Autoimmunity|autoimmune disorders]] are the more common. On the basis of [[etiology]] agranulocytosis can be classified as [[congenital]] and [[Acquired|acquired.]] Common causes of [[acquired]] agranulocytosis include medications like [[clozapine]], [[sulfasalazine]], and [[thioamide]], [[Infection|infections]], [[List of illnesses caused by poor nutrition|nutritional deficiencies]], [[Myelodysplastic syndrome|myelodysplasia]], [[Systemic autoimmune diseases|collagen vascular diseases]], and [[Aplasia|white cell aplasia.]] Agranulocytosis needs to be differentiated from bacterial [[sepsis|sepsis,]] [[aplastic anemia]], [[acute myeloid leukemia]], [[acute lymphoblastic leukemia]], [[cytomegalovirus]], [[Folate deficiency|folic acid deficiency]], and [[Hodgkin's lymphoma|Hodgkin lymphoma]]. The negative [[Prognosis|prognostic factors]] in the course of agranulocytosis are age > 65, [[septic shock]], [[bacteremia]], [[Infections|systemic infections]], [[renal]], [[cardiac]] and [[respiratory]] diseases.The mainstay of treatment of agranulocytosis is medical therapy, including, discontinuation of offending agent, treating [[Infection|infections]] with [[Antibiotics|broad spectrum antibiotics,]] and using [[Granulocyte colony stimulating factor|granulocyte-colony stimulating factor]].
 
Agranulocytosis is defined as severe neutropenia with an [[absolute neutrophil count]] (ANC) <500 cells/microliter.
 
While agranulocytosis technically refers to a reduction in all cells in the leukocyte lineage ([[neutrophils]], [[eosinophils]], and [[basophils]]), the vast majority of cases refer to neutropenia as neutrophils constitute the majority of leukocytes and the primary defense against infection.


==Historical Perspective==
==Historical Perspective==
* Agranulocytosis was first noted around the start of the 20th century on review of blood cell differentials described in patients with [[lupus]], other [[autoimmune disorders]], and with various drug toxicities.<ref name="NLMID39120200R">{{cite journal |author=Dameshek W. |title=Leukopenia and Agranulocytosis.|journal=Oxford University Press. |volume=1|pages=841-52|year=1944|NLM ID 39120200R}}</ref>
* Agranulocytosis was first noted around the beginning of the 20th century on review of blood cell differentials described in patients with [[lupus]], other [[autoimmune disorders]], and with various drug toxicities.<ref name="NLMID39120200R">{{cite journal |author=Dameshek W. |title=Leukopenia and Agranulocytosis.|journal=Oxford University Press. |volume=1|pages=841-52|year=1944|NLM ID 39120200R}}</ref>
==Classification==
==Classification==
Agranulocytosis can be classified as follows:
Agranulocytosis can be classified as [[Congenital disorder|congenital]] or [[Acquired disorder|acquired]]. Each class can be classified to further subgroups as follows:


===== Congenital: =====
===== Congenital =====
* [[Kostmann's syndrome]]
* [[Kostmann syndrome|Kostmann's syndrome]]
* [[Reticular dysgenesis]]
* [[Dysgenesis|Reticular dysgenesis]]
* [[Shwachman-Diamond-Oski syndrome]]
* [[Shwachman-Diamond syndrome]]  
* [[Chediak-Higashi syndrome]]
* [[Chediak-Higashi syndrome]]
* [[Dyskeratosis congenita]]
* [[Dyskeratosis congenita]]
Line 27: Line 23:
** [[Clozapine]]
** [[Clozapine]]
** [[Sulfasalazine]]
** [[Sulfasalazine]]
** [[Thionamide]]
** [[Thioamide]]
* [[Infection]]
* [[Infection]]
** Viral, [[hepatitis B]], [[Epstein-Barr virus]], [[HIV]], [[HCV]]
** [[Virus|Viral infections]] including:
*** [[Hepatitis B]]
*** [[Hepatitis C]]
*** [[Epstein Barr virus|Epstein-Barr virus]]
*** [[HIV]]
** [[Bacterial]]
** [[Bacterial]]
** [[Rickettsial]]
** [[Rickettsial]]
* Collagen vascular diseases
* [[Systemic autoimmune diseases|Collagen vascular diseases]]
** [[SLE]]
** [[SLE]]
** [[Felty's syndrome]]
** [[Felty's syndrome]]
* [[White cell aplasia]]
* White cell [[aplasia]]
* Nutritional deficiency
* [[List of illnesses caused by poor nutrition|Nutritional deficiency]]
** [[Vitamin B12]]
** [[Vitamin B12 deficiency]]
** [[Folic acid]]
** [[Folate deficiency|Folic acid deficiency]]
* [[Myelodysplasia]]
* [[Myelodysplasia]]
* [[Hypoplasia]]
* [[Hypoplasia]]
Line 50: Line 50:
** The drugs or its active [[metabolite]] act as [[hapten]], and binds to [[neutrophil]] [[membrane]].
** The drugs or its active [[metabolite]] act as [[hapten]], and binds to [[neutrophil]] [[membrane]].
** [[Autoantibodies]] are produced as a result of this binding.
** [[Autoantibodies]] are produced as a result of this binding.
** This results in destruction of sensetized [[neutrophils]] by [[phagocytosis]].
** This results in destruction of sensitized [[neutrophils]] by [[phagocytosis]].
** Most common drugs are, [[propylthiouracil]], [[amodiaquine]] , [[Amodiaquine|mono-desethyl amodiaquine]], and [[flecainide]]  
** Most common drugs are [[propylthiouracil]], [[amodiaquine]], [[Amodiaquine|mono-desethyl amodiaquine]], and [[flecainide]].


* '''Direct damage of granulocytes'''
* '''Direct damage of [[Granulocyte|granulocytes]]'''
** Some drugs releases chemically active [[metabolites]].
** Some drugs release chemically active [[metabolites]].
** These metabolites bind to [[Proteins|cytoplasmic proteins]] or [[proteins]] in the [[nucleus]].
** These metabolites bind to [[Proteins|cytoplasmic proteins]] or [[proteins]] in the [[nucleus]].
** This results in direct [[toxicity]] and destruction of [[granulocytes]].
** This results in direct [[toxicity]] and destruction of [[granulocytes]].
** [[Chlorpromazine]]. [[dapsone]], [[clozapine]] and [[procainamide]] are few examples of the drugs.
** [[Chlorpromazine]], [[dapsone]], [[clozapine]], and [[procainamide]] are few examples of these drugs.
** [[Granulocytes]] oxidize [[clozapine]] releasing [[Nitrenium ion|nitrenium ions]].<ref name="UetrechtZahid1997">{{cite journal|last1=Uetrecht|first1=Jack|last2=Zahid|first2=Nasir|last3=Tehim|first3=Ashik|last4=Mim Fu|first4=J|last5=Rakhit|first5=Suman|title=Structural features associated with reactive metabolite formation in clozapine analogues|journal=Chemico-Biological Interactions|volume=104|issue=2-3|year=1997|pages=117–129|issn=00092797|doi=10.1016/S0009-2797(97)00017-3}}</ref>
** [[Granulocytes]] oxidize [[clozapine]] releasing [[Nitrenium ion|nitrenium ions]].<ref name="UetrechtZahid1997">{{cite journal|last1=Uetrecht|first1=Jack|last2=Zahid|first2=Nasir|last3=Tehim|first3=Ashik|last4=Mim Fu|first4=J|last5=Rakhit|first5=Suman|title=Structural features associated with reactive metabolite formation in clozapine analogues|journal=Chemico-Biological Interactions|volume=104|issue=2-3|year=1997|pages=117–129|issn=00092797|doi=10.1016/S0009-2797(97)00017-3}}</ref>
** [[Nitrenium ion|Nitrenium ions]] bind irreversibly to [[granulocytes]] and its [[precursor]] cells resulting in [[toxic]] destruction of these cells.
** [[Nitrenium ion|Nitrenium ions]] bind irreversibly to [[granulocytes]] and its [[precursor]] cells resulting in [[toxic]] destruction of these [[Cell (biology)|cells]].


==Causes==
==Causes==
Line 74: Line 74:
* [[Chemotherapy]]  
* [[Chemotherapy]]  
* [[Bone marrow transplant]]  
* [[Bone marrow transplant]]  
* [[SLE|Systemic lupus erythematosus(SLE)]]  
* [[Systemic lupus erythematosus]] ([[SLE]])
* [[Rheumatoid arthritis]]  
* [[Rheumatoid arthritis]]  
* [[HIV]]  
* [[HIV]]  
Line 91: Line 91:
* [[Folic acid deficiency]]
* [[Folic acid deficiency]]
* [[Hodgkin lymphoma]]
* [[Hodgkin lymphoma]]
* [[Non Hodgkin lymphoma]]
* [[Non-Hodgkin lymphoma]]
* [[Wegener Granulomatosis]]
* [[Wegener granulomatosis]]


==Epidemiology and Demographics==
==Epidemiology and Demographics==
* Agranulocytosis is extremly [[rare]] condition
* Agranulocytosis is an extremely [[rare]] condition.
* The overall [[Incidence (epidemiology)|incidence rate]] is 7.2 per million per year<ref name="Strom1992">{{cite journal|last1=Strom|first1=Brian L.|title=Descriptive Epidemiology of Agranulocytosis|journal=Archives of Internal Medicine|volume=152|issue=7|year=1992|pages=1475|issn=0003-9926|doi=10.1001/archinte.1992.00400190095018}}</ref>
* The overall [[Incidence (epidemiology)|incidence rate]] is 7.2 per million per year.<ref name="Strom1992">{{cite journal|last1=Strom|first1=Brian L.|title=Descriptive Epidemiology of Agranulocytosis|journal=Archives of Internal Medicine|volume=152|issue=7|year=1992|pages=1475|issn=0003-9926|doi=10.1001/archinte.1992.00400190095018}}</ref>
* It can occur in all [[Race|races]] and any age group
* It can occur in all [[Race|races]] and any age group.
* The [[acquired]] type of agraulocytosis is more common in older individuals
* The [[acquired]] type of agranulocytosis is more common in older individuals. While [[inherited]] type is commonly seen in children.
* [[Inherited]] type is commonly seen in children.
* The risk of agranulocytosis is seen higher in women.<ref name="AlvirLieberman1993">{{cite journal|last1=Alvir|first1=Jose Ma. J.|last2=Lieberman|first2=Jeffrey A.|last3=Safferman|first3=Allan Z.|last4=Schwimmer|first4=Jeffrey L.|last5=Schaaf|first5=John A.|title=Clozapine-Induced Agranulocytosis -- Incidence and Risk Factors in the United States|journal=New England Journal of Medicine|volume=329|issue=3|year=1993|pages=162–167|issn=0028-4793|doi=10.1056/NEJM199307153290303}}</ref>
* The risk of agranulocytosis is seen higher in women<ref name="AlvirLieberman1993">{{cite journal|last1=Alvir|first1=Jose Ma. J.|last2=Lieberman|first2=Jeffrey A.|last3=Safferman|first3=Allan Z.|last4=Schwimmer|first4=Jeffrey L.|last5=Schaaf|first5=John A.|title=Clozapine-Induced Agranulocytosis -- Incidence and Risk Factors in the United States|journal=New England Journal of Medicine|volume=329|issue=3|year=1993|pages=162–167|issn=0028-4793|doi=10.1056/NEJM199307153290303}}</ref>


==Risk Factors==
==Risk Factors==
Line 112: Line 111:
** [[Autoimmune disorders]]
** [[Autoimmune disorders]]
* Genetic susceptibility
* Genetic susceptibility
** Association between HLA-B38, DQW3 haplotype and [[clozapine]] induced agranulocytosis is seen in Ashkenazi Jews<ref name="pmid7579351">{{cite journal |vauthors=Corzo D, Yunis JJ, Salazar M, Lieberman JA, Howard A, Awdeh Z, Alper CA, Yunis EJ |title=The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups |journal=Blood |volume=86 |issue=10 |pages=3835–40 |date=November 1995 |pmid=7579351 |doi= |url=}}</ref>
** Association between [[HLA-B]]38, DQW3 haplotype, and [[clozapine]] induced agranulocytosis is seen in Ashkenazi Jews.<ref name="pmid7579351">{{cite journal |vauthors=Corzo D, Yunis JJ, Salazar M, Lieberman JA, Howard A, Awdeh Z, Alper CA, Yunis EJ |title=The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups |journal=Blood |volume=86 |issue=10 |pages=3835–40 |date=November 1995 |pmid=7579351 |doi= |url=}}</ref>
** HLA DRB1*08032 allele has a strong suseptibility to [[methimazole]] induced agranulocytosis<ref name="Tamai1996">{{cite journal|last1=Tamai|first1=Hajime|title=Association between the DRB1*08032 Histocompatibility Antigen and Methimazole-Induced Agranulocytosis in Japanese Patients with Graves Disease|journal=Annals of Internal Medicine|volume=124|issue=5|year=1996|pages=490|issn=0003-4819|doi=10.7326/0003-4819-124-5-199603010-00005}}</ref>
** [[HLA-DRB1|HLA DRB1]]*08032 allele has a strong susceptibility to [[methimazole]] induced agranulocytosis.<ref name="Tamai1996">{{cite journal|last1=Tamai|first1=Hajime|title=Association between the DRB1*08032 Histocompatibility Antigen and Methimazole-Induced Agranulocytosis in Japanese Patients with Graves Disease|journal=Annals of Internal Medicine|volume=124|issue=5|year=1996|pages=490|issn=0003-4819|doi=10.7326/0003-4819-124-5-199603010-00005}}</ref>


==Screening==
==Screening==
There are no routine screening recommendations for [[agranulocytosis]]. It is typically identified incidentally on routine blood work or while monitoring after [[cytotoxic]] therapy.<ref name="PMID21258094">{{cite journal |author=Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. |title=Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america|journal=Clin Infect Dis. |volume=52 |issue=4 |pages=e56-95 |year=2011 |pmid=21258094 |doi=|url=http://www.ncbi.nlm.nih.gov/pubmed/21258094}}</ref>
There are no routine screening recommendations for agranulocytosis. It is typically identified incidentally on routine blood work or while monitoring after [[cytotoxic]] therapy.<ref name="PMID21258094">{{cite journal |author=Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. |title=Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america|journal=Clin Infect Dis. |volume=52 |issue=4 |pages=e56-95 |year=2011 |pmid=21258094 |doi=|url=http://www.ncbi.nlm.nih.gov/pubmed/21258094}}</ref>


==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==
Line 122: Line 121:
* [[Neutropenia]], and progression to agranulocytosis, occurs in either a dose-dependent or [[Idiosyncratic reaction|idiosyncratic]] process dependent upon the [[etiology]].  
* [[Neutropenia]], and progression to agranulocytosis, occurs in either a dose-dependent or [[Idiosyncratic reaction|idiosyncratic]] process dependent upon the [[etiology]].  


* Neutropenia caused by [[cytotoxic]] [[chemotherapy]] or malignant [[bone marrow]] infiltration is typically dose-dependent or related to tumor burden, as opposed to  
* Neutropenia caused by [[cytotoxic]] [[chemotherapy]] or malignant [[bone marrow]] infiltration is typically dose-dependent or related to tumor burden, as opposed to idiosyncratic, and  [[Immune-mediated disease|immune-mediated]] [[neutropenia]] that occurs independently.  
* [[Idiosyncratic reaction|Idiosyncratic]], and  [[Immune-mediated disease|immune-mediated]] [[neutropenia]] occur independently.


===Complications===
===Complications===
The major complications of agranulocytosis are as follows<ref name="AndrèsMaloisel20102">{{cite journal|last1=Andrès|first1=Emmanuel|last2=Maloisel|first2=Frédéric|last3=Zimmer|first3=Jacques|title=The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis|journal=British Journal of Haematology|year=2010|issn=00071048|doi=10.1111/j.1365-2141.2010.08104.x}}</ref>
The major complications of agranulocytosis are as follows:<ref name="AndrèsMaloisel20102">{{cite journal|last1=Andrès|first1=Emmanuel|last2=Maloisel|first2=Frédéric|last3=Zimmer|first3=Jacques|title=The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis|journal=British Journal of Haematology|year=2010|issn=00071048|doi=10.1111/j.1365-2141.2010.08104.x}}</ref>
* [[Septicemia]]
* [[Septicemia]]
* [[Bacterial infections]]
* [[Bacterial infections]]
Line 136: Line 134:
===Prognosis===
===Prognosis===
The negative prognostic factors for agranulocytosis are:<ref name="AndrèsMaloisel2010">{{cite journal|last1=Andrès|first1=Emmanuel|last2=Maloisel|first2=Frédéric|last3=Zimmer|first3=Jacques|title=The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis|journal=British Journal of Haematology|year=2010|issn=00071048|doi=10.1111/j.1365-2141.2010.08104.x}}</ref>
The negative prognostic factors for agranulocytosis are:<ref name="AndrèsMaloisel2010">{{cite journal|last1=Andrès|first1=Emmanuel|last2=Maloisel|first2=Frédéric|last3=Zimmer|first3=Jacques|title=The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis|journal=British Journal of Haematology|year=2010|issn=00071048|doi=10.1111/j.1365-2141.2010.08104.x}}</ref>
* [[Neutrophil|Neutrophil count]] at the time of diagnosis <0.1 × 109/l
* [[Neutrophil|Neutrophil count]] at the time of diagnosis <0.1 × 10<sup>9</sup> cells/L
 
* Age > 65 years old
* Severe infections like [[septic shock]], [[bacteremia]]
* Pre existence of systemic infections, [[renal]], [[cardiac]] and [[respiratory]] diseases


* Age > 65yrs
==Diagnosis==
* Advancement in to severe infections like [[septic shock]], [[bacteremia]]
* Pre existance of systemic infections, [[renal]], [[cardiac]] and [[respiratory]] diseases.


==History and Symptoms==
=== Diagnostic Study of Choice ===
The diagnosis of agranulocytosis is based on the laboratory finding when the number of [[Granulocyte|granulocytes]] ([[Neutrophils]], [[Basophils]], [[Eosinophils]]) is below an absolute count of 500 cells/mcL.


==== History ====
=== History and Symptoms ===
History of patients with agranulocytosis should focus on any history of:
History of patients with agranulocytosis should focus on any history of:<ref name="AndrèsZimmer2014">{{cite journal|last1=Andrès|first1=Emmanuel|last2=Zimmer|first2=Jacques|last3=Mecili|first3=Mustapha|last4=Weitten|first4=Thierry|last5=Alt|first5=Martine|last6=Maloisel|first6=Frédéric|title=Clinical presentation and management of drug-induced agranulocytosis|journal=Expert Review of Hematology|volume=4|issue=2|year=2014|pages=143–151|issn=1747-4086|doi=10.1586/ehm.11.12}}</ref>
* [[Malignancy]]
* [[Malignancy]]
* [[Infection]]
* [[Infection]]
* [[Autoimmune disorders]]  
* [[Autoimmune disorders]]  
* [[Medication|Medications]]
* [[Medication|Medications]]
 
Common symptoms include:<ref name="AndrèsZimmer2014" />
==== Symptoms ====
Common symptoms include:
*[[Fever]]
*[[Fever]]
*Frequent [[infections]]
*Symptoms of frequent [[infections]]
*Unusual [[redness]], [[pain]], or [[swelling]] around a wound
*Unusual [[redness]], [[pain]], or [[swelling]] around a wound
*Mouth [[ulcers]]
*Mouth [[ulcers]]
Line 163: Line 162:
*Shaking [[chills]]
*Shaking [[chills]]


==Physical Examination==
===Physical Examination===
Common signs of agranulocytosis may include:
Common signs of agranulocytosis may include:
*[[Fever]]
*[[Fever]]
Line 172: Line 171:
*[[Hyperbilirubinemia|Jaundice]]
*[[Hyperbilirubinemia|Jaundice]]
*[[Wheeze|Wheezes]]
*[[Wheeze|Wheezes]]
*[[rales]]
*[[Rales]]
*[[Joint swelling]] or deformity
*[[Joint swelling]] or deformity
*[[Rashes]]
*[[Rashes]]
Line 184: Line 183:
* [[Rheumatoid factor]]
* [[Rheumatoid factor]]
* Peripheral [[Flow cytometry|blood flow cytometry]]  
* Peripheral [[Flow cytometry|blood flow cytometry]]  
* [[Antinuclear antibodies|ANA,antinuclear antibody]]  
* [[Anti-nuclear antibody|Antinuclear antibody]] ([[Antinuclear antibodies|ANA]])
* [[Immunoglobulin|Serum immunoglobulin study]]
* [[Immunoglobulin|Serum immunoglobulin study]]
* [[Vitamin B12]] and [[Folate levels]]
* [[Vitamin B12]] and [[Folate levels]]
* [[HIV]] testing
* [[HIV]] testing
=== Electrocardiogram ===
There are no ECG findings associated with agranulocytosis.
=== X-ray ===
There are no x-ray findings associated with agranulocytosis. However, an x-ray may be helpful in the diagnosis of underlying cause or complications of agranulocytosis.
=== Echocardiography or Ultrasound ===
There are no echocardiography/ultrasound findings associated with agranulocytosis.
=== CT scan ===
There are no CT scan findings associated with agranulocytosis. However, a CT scan may be helpful in the diagnosis of underlying cause or complications of agranulocytosis.
=== MRI ===
There are no MRI findings associated with agranulocytosis. However, a MRI may be helpful in the diagnosis of underlying cause or complications of agranulocytosis.
=== Other Imaging Findings ===
There are no other imaging findings associated with agranulocytosis.
=== Other Diagnostic Studies ===
There are no other diagnostic studies associated with agranulocytosis.


==Treatment==
==Treatment==
==Medical Therapy==
===Medical Therapy===
* '''Discontinuation of the offending agent'''
* '''Discontinuation of the offending agent'''
** Identifying and removing the offending agents
** Identifying and removing the offending agents
** It takes about 1-3 weeks for [[neutropenia]] to resolve after stopping the offending drug
** It takes about 1-3 weeks for [[neutropenia]] to resolve after stopping the offending drug.


* '''Treat the associated infections and conditions'''
* '''Treat the associated infections and conditions'''
** In cases of [[febrile neutropenia]], [[empiric]] [[antibiotics]] should be administered [[intravenously]] as early as possible<ref name="TesfaKeisu2009">{{cite journal|last1=Tesfa|first1=Daniel|last2=Keisu|first2=Marianne|last3=Palmblad|first3=Jan|title=Idiosyncratic drug-induced agranulocytosis: Possible mechanisms and management|journal=American Journal of Hematology|volume=84|issue=7|year=2009|pages=428–434|issn=03618609|doi=10.1002/ajh.21433}}</ref>
** In cases of [[febrile neutropenia]], [[Empiric therapy|empiric antibiotics]] should be administered [[intravenously]] as early as possible.<ref name="TesfaKeisu2009">{{cite journal|last1=Tesfa|first1=Daniel|last2=Keisu|first2=Marianne|last3=Palmblad|first3=Jan|title=Idiosyncratic drug-induced agranulocytosis: Possible mechanisms and management|journal=American Journal of Hematology|volume=84|issue=7|year=2009|pages=428–434|issn=03618609|doi=10.1002/ajh.21433}}</ref>
** Before starting the [[Antibiotic|antibiotics]], blood, urine and [[Sputum culture|sputum cultures]] should be withdrawn
** Before starting the [[Antibiotic|antibiotics]], blood, urine and [[Sputum culture|sputum cultures]] should be withdrawn.
** [[Antibiotic]] coverage should be [[bactericidal]] for most common [[pathogens]]<ref name="PMID4994878">{{cite journal |author=Schimpff S, Satterlee W, Young VM, Serpick A |title=Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia |journal=N Engl J Med. |volume=284 |issue=19 |pages=1061-5 |year=1971 |pmid=4994878 |doi=|url=https://www.ncbi.nlm.nih.gov/pubmed/4994878}}</ref><ref name="PMID16625125">{{cite journal |author=Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M |title=Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock |journal=Crit Care Med. |volume=34 |issue=6 |pages=1589-96 |year=2006 |pmid=16625125 |doi=|url=https://www.ncbi.nlm.nih.gov/pubmed/16625125}}</ref><ref name="PMID24752269">{{cite journal |author=Rosa RG, Goldani LZ. |title=Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia |journal=Antimicrob Agents Chemother. |volume=58 |issue=7|pages=3799-803 |year=2014 |pmid=24752269 |doi=|url=https://www.ncbi.nlm.nih.gov/pubmed/24752269}}</ref>
** [[Antibiotic]] coverage should be [[bactericidal]] for most common [[pathogens]].<ref name="PMID4994878">{{cite journal |author=Schimpff S, Satterlee W, Young VM, Serpick A |title=Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia |journal=N Engl J Med. |volume=284 |issue=19 |pages=1061-5 |year=1971 |pmid=4994878 |doi=|url=https://www.ncbi.nlm.nih.gov/pubmed/4994878}}</ref><ref name="PMID16625125">{{cite journal |author=Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M |title=Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock |journal=Crit Care Med. |volume=34 |issue=6 |pages=1589-96 |year=2006 |pmid=16625125 |doi=|url=https://www.ncbi.nlm.nih.gov/pubmed/16625125}}</ref><ref name="PMID24752269">{{cite journal |author=Rosa RG, Goldani LZ. |title=Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia |journal=Antimicrob Agents Chemother. |volume=58 |issue=7|pages=3799-803 |year=2014 |pmid=24752269 |doi=|url=https://www.ncbi.nlm.nih.gov/pubmed/24752269}}</ref>
** [[Central venous catheters]] and other indwelling devices should be removed when possible if there is suspicion for [[infection]] or with positive [[Blood culture|blood cultures]].
** [[Central venous catheters]] and other indwelling devices should be removed when possible if there is suspicion for [[infection]] or with positive [[Blood culture|blood cultures]].
* '''Use of granulocyte-colony stimulating factor'''
* '''Use of granulocyte-colony stimulating factor'''
**  [[Granulocyte colony stimulating factor|Granulocyte-colony stimulating factor]] G-CSF has shown excellent results in patients with drug induced agranulocytosis and severe [[Infection|infection.]]
**  [[Granulocyte colony stimulating factor|Granulocyte-colony stimulating factor]] (G-CSF) has shown excellent results in patients with drug induced agranulocytosis and severe [[Infection|infection.]]<ref name="AndrèsZimmer2014" />
** It is very beneficial in patiets with [[neutropenia]] secondry to [[chemotherapy]]
** It is mostly beneficial in patients with [[neutropenia]] secondary to [[chemotherapy]].


* '''Immune suppression'''
* '''Immune suppression'''
** In [[neutropenia]] with [[autoimmune diseases]], [[prednisone]] is used for [[Immunosuppression|immune suppression]]
** In [[neutropenia]] with [[autoimmune diseases]], [[prednisone]] is used for [[immunosuppression]].


* '''Bone marrow transplant'''
* '''Bone marrow transplant'''
** When other treatments do not work, [[Bone marrow transplantation|bone marrow transplant]] is an option
** When other treatments do not work, [[Bone marrow transplantation|bone marrow transplant]] is an option.
** It is more successful in patients aged<40 yrs and with good health.
** It is more successful in patients aged <40 years old in good health.


===Surgery===
===Surgery===
There are no surgical treatments for [[agranulocytosis]]. In patients with [[neutropenic fever]], surgical intervention may be necessary depending on the source of infection.<ref name="PMID21258094">{{cite journal |author=Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. |title=Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america|journal=Clin Infect Dis. |volume=52 |issue=4 |pages=e56-95 |year=2011 |pmid=21258094 |doi=|url=http://www.ncbi.nlm.nih.gov/pubmed/21258094}}</ref>
There are no surgical treatments for agranulocytosis. However, in patients with [[neutropenic fever]], surgical intervention may be necessary depending on the source of infection.<ref name="PMID21258094">{{cite journal |author=Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. |title=Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america|journal=Clin Infect Dis. |volume=52 |issue=4 |pages=e56-95 |year=2011 |pmid=21258094 |doi=|url=http://www.ncbi.nlm.nih.gov/pubmed/21258094}}</ref>


===Prevention===
===Primary Prevention===
Prevention of agranulocytosis is dependent upon:
Primary prevention of agranulocytosis is dependent upon:
* Avoiding certain [[medications]]
* Avoiding certain [[medications]]
* Treatment of underlying conditions
* Occasionally, when agranulocytosis is anticipated, such as in the setting of [[Chemotherapy|cytotoxic chemotherapy]], recombinant [[Granulocyte-colony stimulating factor|G-CSF]] ([[Granulocyte colony stimulating factor|granulocyte-colony stimulating factor]]) can be considered to speed [[myeloid]] reconstitution.
* Occasionally, when agranulocytosis is anticipated, such as in the setting of [[Chemotherapy|cytotoxic chemotherapy]], recombinant [[Granulocyte-colony stimulating factor|G-CSF]] ([[Granulocyte colony stimulating factor|granulocyte-colony stimulating factor]]) can be considered to speed [[myeloid]] reconstitution
===Secondary Prevention===
 
Effective measures for the secondary prevention of agranulocytosis include early detection and treatment of underlying conditions.
==See also==
==See also==
* [[Complete blood count]]
* [[Complete blood count]]
Line 227: Line 247:
{{reflist|2}}
{{reflist|2}}


[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Hematology]]
 
[[Category:Infectious disease]]
{{WS}}
[[Category:Oncology]]
{{WH}}
[[Category:Up-To-Date]]

Latest revision as of 20:19, 29 July 2020

WikiDoc Resources for Agranulocytosis

Articles

Most recent articles on Agranulocytosis

Most cited articles on Agranulocytosis

Review articles on Agranulocytosis

Articles on Agranulocytosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Agranulocytosis

Images of Agranulocytosis

Photos of Agranulocytosis

Podcasts & MP3s on Agranulocytosis

Videos on Agranulocytosis

Evidence Based Medicine

Cochrane Collaboration on Agranulocytosis

Bandolier on Agranulocytosis

TRIP on Agranulocytosis

Clinical Trials

Ongoing Trials on Agranulocytosis at Clinical Trials.gov

Trial results on Agranulocytosis

Clinical Trials on Agranulocytosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Agranulocytosis

NICE Guidance on Agranulocytosis

NHS PRODIGY Guidance

FDA on Agranulocytosis

CDC on Agranulocytosis

Books

Books on Agranulocytosis

News

Agranulocytosis in the news

Be alerted to news on Agranulocytosis

News trends on Agranulocytosis

Commentary

Blogs on Agranulocytosis

Definitions

Definitions of Agranulocytosis

Patient Resources / Community

Patient resources on Agranulocytosis

Discussion groups on Agranulocytosis

Patient Handouts on Agranulocytosis

Directions to Hospitals Treating Agranulocytosis

Risk calculators and risk factors for Agranulocytosis

Healthcare Provider Resources

Symptoms of Agranulocytosis

Causes & Risk Factors for Agranulocytosis

Diagnostic studies for Agranulocytosis

Treatment of Agranulocytosis

Continuing Medical Education (CME)

CME Programs on Agranulocytosis

International

Agranulocytosis en Espanol

Agranulocytosis en Francais

Business

Agranulocytosis in the Marketplace

Patents on Agranulocytosis

Experimental / Informatics

List of terms related to Agranulocytosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Daniel A. Gerber, M.D. [3] Nazia Fuad M.D.

Synonyms and Keywords: Agranulosis, granulocytopenia, neutropenia

Overview

Agranulocytosis is defined as marked reduction in the number of granulocytes (Neutrophils, Basophils, Eosinophils) below an absolute count of 500 cells/mcL. It is a rare condition with incidence of 1 to 5 cases per million population per year. Agranulocytosis results in frequent chronic bacterial infections of skin, lung, and throat. Patients can present with sepsis and fever. Among many risk factors, medications, combination therapy with ACE inhibitors and interferon, cytotoxic chemotherapy, hematologic malignancies, and autoimmune disorders are the more common. On the basis of etiology agranulocytosis can be classified as congenital and acquired. Common causes of acquired agranulocytosis include medications like clozapine, sulfasalazine, and thioamide, infections, nutritional deficiencies, myelodysplasia, collagen vascular diseases, and white cell aplasia. Agranulocytosis needs to be differentiated from bacterial sepsis, aplastic anemia, acute myeloid leukemia, acute lymphoblastic leukemia, cytomegalovirus, folic acid deficiency, and Hodgkin lymphoma. The negative prognostic factors in the course of agranulocytosis are age > 65, septic shock, bacteremia, systemic infections, renal, cardiac and respiratory diseases.The mainstay of treatment of agranulocytosis is medical therapy, including, discontinuation of offending agent, treating infections with broad spectrum antibiotics, and using granulocyte-colony stimulating factor.

Historical Perspective

  • Agranulocytosis was first noted around the beginning of the 20th century on review of blood cell differentials described in patients with lupus, other autoimmune disorders, and with various drug toxicities.[1]

Classification

Agranulocytosis can be classified as congenital or acquired. Each class can be classified to further subgroups as follows:

Congenital
Acquired

Pathophysiology

Agranulocytosis develops as a result of the following mechanisms:[2]

Causes

Agranulocytosis can be congenital or acquired. Common causes of acquired agranulocytosis include:[4][5]

Differentiating Agranulocytosis from Other Diseases

Consider the following differential when evaluating a patient with agranulocytosis:

Epidemiology and Demographics

  • Agranulocytosis is an extremely rare condition.
  • The overall incidence rate is 7.2 per million per year.[6]
  • It can occur in all races and any age group.
  • The acquired type of agranulocytosis is more common in older individuals. While inherited type is commonly seen in children.
  • The risk of agranulocytosis is seen higher in women.[7]

Risk Factors

Risk factors for agranulocytosis include:

Screening

There are no routine screening recommendations for agranulocytosis. It is typically identified incidentally on routine blood work or while monitoring after cytotoxic therapy.[13]

Natural History, Complications, and Prognosis

Natural History

Complications

The major complications of agranulocytosis are as follows:[14]

Prognosis

The negative prognostic factors for agranulocytosis are:[15]

Diagnosis

Diagnostic Study of Choice

The diagnosis of agranulocytosis is based on the laboratory finding when the number of granulocytes (Neutrophils, Basophils, Eosinophils) is below an absolute count of 500 cells/mcL.

History and Symptoms

History of patients with agranulocytosis should focus on any history of:[16]

Common symptoms include:[16]

Physical Examination

Common signs of agranulocytosis may include:

Laboratory Findings

The following tests should be performed after careful medication history:

Some patients may need:

Electrocardiogram

There are no ECG findings associated with agranulocytosis.

X-ray

There are no x-ray findings associated with agranulocytosis. However, an x-ray may be helpful in the diagnosis of underlying cause or complications of agranulocytosis.

Echocardiography or Ultrasound

There are no echocardiography/ultrasound findings associated with agranulocytosis.

CT scan

There are no CT scan findings associated with agranulocytosis. However, a CT scan may be helpful in the diagnosis of underlying cause or complications of agranulocytosis.

MRI

There are no MRI findings associated with agranulocytosis. However, a MRI may be helpful in the diagnosis of underlying cause or complications of agranulocytosis.

Other Imaging Findings

There are no other imaging findings associated with agranulocytosis.

Other Diagnostic Studies

There are no other diagnostic studies associated with agranulocytosis.

Treatment

Medical Therapy

  • Discontinuation of the offending agent
    • Identifying and removing the offending agents
    • It takes about 1-3 weeks for neutropenia to resolve after stopping the offending drug.
  • Bone marrow transplant
    • When other treatments do not work, bone marrow transplant is an option.
    • It is more successful in patients aged <40 years old in good health.

Surgery

There are no surgical treatments for agranulocytosis. However, in patients with neutropenic fever, surgical intervention may be necessary depending on the source of infection.[13]

Primary Prevention

Primary prevention of agranulocytosis is dependent upon:

Secondary Prevention

Effective measures for the secondary prevention of agranulocytosis include early detection and treatment of underlying conditions.

See also

References

  1. ↑ Dameshek W. (1944). "Leukopenia and Agranulocytosis". Oxford University Press. 1: 841–52. Text "NLM ID 39120200R" ignored (help)
  2. ↑ Pontikoglou, Charalampos; Papadaki, Helen A. (2010). "Idiosyncratic Drug-Induced Agranulocytosis: The Paradigm of Deferiprone". Hemoglobin. 34 (3): 291–304. doi:10.3109/03630269.2010.484791. ISSN 0363-0269.
  3. ↑ Uetrecht, Jack; Zahid, Nasir; Tehim, Ashik; Mim Fu, J; Rakhit, Suman (1997). "Structural features associated with reactive metabolite formation in clozapine analogues". Chemico-Biological Interactions. 104 (2–3): 117–129. doi:10.1016/S0009-2797(97)00017-3. ISSN 0009-2797.
  4. ↑ Andersohn F, Konzen C, Garbe E. (2007). "Systematic review: agranulocytosis induced by nonchemotherapy drugs". Ann Internal Med. 146(9): 657–65. Text "PMID 17470834" ignored (help)
  5. ↑ Andersohn, Frank; Konzen, Christine; Garbe, Edeltraut (2007). "Systematic Review: Agranulocytosis Induced by Nonchemotherapy Drugs". Annals of Internal Medicine. 146 (9): 657. doi:10.7326/0003-4819-146-9-200705010-00009. ISSN 0003-4819.
  6. ↑ Strom, Brian L. (1992). "Descriptive Epidemiology of Agranulocytosis". Archives of Internal Medicine. 152 (7): 1475. doi:10.1001/archinte.1992.00400190095018. ISSN 0003-9926.
  7. ↑ Alvir, Jose Ma. J.; Lieberman, Jeffrey A.; Safferman, Allan Z.; Schwimmer, Jeffrey L.; Schaaf, John A. (1993). "Clozapine-Induced Agranulocytosis -- Incidence and Risk Factors in the United States". New England Journal of Medicine. 329 (3): 162–167. doi:10.1056/NEJM199307153290303. ISSN 0028-4793.
  8. ↑ Andrès E, Zimmer J, Affenberger S, Federici L, Alt M, Maloisel F. (2006). "Idiosyncratic drug-induced agranulocytosis: Update of an old disorder". Eur J Intern Med. 17 (8): 529–35. Text "pmid 17142169" ignored (help)
  9. ↑ Levy M, Kelly JP, Kaufman DW, Shapiro S (October 1993). "Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: a report from the international agranulocytosis and aplastic anemia study". Ann. Hematol. 67 (4): 187–90. PMID 8218540.
  10. ↑ Casato, Milyia; Pucillo, Leopoldo P.; Leoni, Marco; di Lullo, Luca; Gabrielli, Armando; Sansonno, Domenico; Dammacco, Franco; Danieli, Giovanni; Bonomo, Lorenzo (1995). "Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: Evidence for a synergistic hematologic toxicity". The American Journal of Medicine. 99 (4): 386–391. doi:10.1016/S0002-9343(99)80186-7. ISSN 0002-9343.
  11. ↑ Corzo D, Yunis JJ, Salazar M, Lieberman JA, Howard A, Awdeh Z, Alper CA, Yunis EJ (November 1995). "The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups". Blood. 86 (10): 3835–40. PMID 7579351.
  12. ↑ Tamai, Hajime (1996). "Association between the DRB1*08032 Histocompatibility Antigen and Methimazole-Induced Agranulocytosis in Japanese Patients with Graves Disease". Annals of Internal Medicine. 124 (5): 490. doi:10.7326/0003-4819-124-5-199603010-00005. ISSN 0003-4819.
  13. ↑ 13.0 13.1 Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. (2011). "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america". Clin Infect Dis. 52 (4): e56–95. PMID 21258094.
  14. ↑ Andrès, Emmanuel; Maloisel, Frédéric; Zimmer, Jacques (2010). "The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis". British Journal of Haematology. doi:10.1111/j.1365-2141.2010.08104.x. ISSN 0007-1048.
  15. ↑ Andrès, Emmanuel; Maloisel, Frédéric; Zimmer, Jacques (2010). "The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis". British Journal of Haematology. doi:10.1111/j.1365-2141.2010.08104.x. ISSN 0007-1048.
  16. ↑ 16.0 16.1 16.2 Andrès, Emmanuel; Zimmer, Jacques; Mecili, Mustapha; Weitten, Thierry; Alt, Martine; Maloisel, Frédéric (2014). "Clinical presentation and management of drug-induced agranulocytosis". Expert Review of Hematology. 4 (2): 143–151. doi:10.1586/ehm.11.12. ISSN 1747-4086.
  17. ↑ Tesfa, Daniel; Keisu, Marianne; Palmblad, Jan (2009). "Idiosyncratic drug-induced agranulocytosis: Possible mechanisms and management". American Journal of Hematology. 84 (7): 428–434. doi:10.1002/ajh.21433. ISSN 0361-8609.
  18. ↑ Schimpff S, Satterlee W, Young VM, Serpick A (1971). "Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia". N Engl J Med. 284 (19): 1061–5. PMID 4994878.
  19. ↑ Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M (2006). "Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock". Crit Care Med. 34 (6): 1589–96. PMID 16625125.
  20. ↑ Rosa RG, Goldani LZ. (2014). "Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia". Antimicrob Agents Chemother. 58 (7): 3799–803. PMID 24752269.
Retrieved from "https://www.wikidoc.org/index.php?title=Agranulocytosis&oldid=1634473"